Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-9 of 9
Keywords: Ingenol mebutate
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 29–31.
Published Online: 11 August 2016
... BCCs with ingenol mebutate without post-inflammatory scarring. At 8-month follow-up, the patient shows no recurrence of the treated lesions. Conclusion: Ingenol mebutate can be used to treat (superficial) BCCs in patients with Gorlin-Goltz syndrome as an additional modality. Close clinical follow-up...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 4–6.
Published Online: 11 August 2016
...Olivier Gaide; Vincent Cattin Ingenol mebutate induces strong inflammation after a single application already. This must be taken into account when prescribing the drug, as mistakes in the application may results in severe side effects. Here, we report the case of a 72-year-old woman who applied...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 7–8.
Published Online: 11 August 2016
... be particularly challenging. We report the case of a patient who failed to respond to most AK treatments, including 5-FU, imiquimod and photodynamic therapy, but responded to ingenol mebutate. We started with 3 applications of 150 μg/g (registered treatment of the scalp) and also 2 applications of 500 μg/g...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 14–16.
Published Online: 11 August 2016
...Mosab T. Mohanna; Günther F.L. Hofbauer Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis (AK). We report 2 cases with off-label use of IM. The first case of bowenoid AK was treated with 150 μg...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 1–3.
Published Online: 11 August 2016
... treatment with 5% imiquimod cream - also with intensified application - failed. After 2 cycles thrice daily, consecutive applications of 150 μg/g ingenol mebutate gel at 3 weeks' interval, the lesions cleared completely. Surprisingly, no pustular or crusting reaction or other side effect occurred contrary...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 17–19.
Published Online: 11 August 2016
...Ahmed Alkhalaf; Günther F.L. Hofbauer Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 9–13.
Published Online: 11 August 2016
...Carlo Mainetti; Caroline Guillod; Sandra Leoni-Parvex Ingenol mebutate (IM) has recently been approved for the topical treatment of actinic keratoses. It appears to have a dual mechanism of action: rapid necrosis after gel application and a subsequent immune-mediated response, which targets any...
Journal Articles
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 20–23.
Published Online: 11 August 2016
... keratoses on both cheeks and the forehead and received treatment by ingenol mebutate 150 µg/g gel daily on 3 consecutive days on his right cheek and methyl aminolevulinate (MAL) photodynamic therapy activated by daylight (MAL-dPDT) on the forehead and the left cheek. MAL-dPDT treatment proved a feasible...
Journal Articles
Subject Area:
Topic Article Package: Melanoma
,
Topic Article Package: Melanoma 2019
,
Dermatology
,
Immunology and Allergy
Journal:
Dermatology
Dermatology (2016) 232 (Suppl. 1): 24–28.
Published Online: 11 August 2016
..., including surgery, cryotherapy, radiotherapy and topical imiquimod. Up to date surgical excision remains the treatment of choice with the lowest recurrence rate. Recently, a new topical treatment with ingenol mebutate has been described to be efficacious and well tolerated in the treatment of melanoma...